TNG908 for Solid Tumors

Recruiting at20 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: Tango Therapeutics, Inc.

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial is testing TNG908, an oral drug, in patients with advanced or metastatic solid tumors that have an MTAP deletion. The drug works by blocking a protein that helps these specific cancer cells grow. The study will see if this treatment can help slow down or stop the cancer.

Research Team

Maxim Pimkin, MD, PhD

Principal Investigator

Tango Therapeutics, Inc.

Eligibility Criteria

This trial is for adults (18+) with advanced or metastatic solid tumors that lack the MTAP protein, confirmed by specific tests. Participants must have tried standard treatments if available, be in fairly good health with a performance score of 0 to 1 or ≥70, and have functioning major organs. Pregnant women and those with significant medical conditions, allergies to TNG908, uncontrolled illnesses affecting study compliance, active infections requiring therapy, other cancers, certain heart diseases or HIV not meeting specific criteria are excluded.

Inclusion Criteria

I am 18 years old or older.

My tumor lacks the MTAP gene or protein.

I am fully active or able to carry out light work.

Exclusion Criteria

I am willing and able to follow the study's schedule and procedures.

I have another cancer besides the one being treated.

I am currently on medication for an infection.

Treatment Details

Interventions

• TNG908 (PRMT5 Inhibitor)

Trial Overview TNG908 is being tested on patients with MTAP-deleted solid tumors. It's an oral drug designed to inhibit PRMT5. The trial has two parts: dose escalation to find the safe amount people can take without too many side effects and dose expansion focusing on how well it works in particular tumor types.

Participant Groups

Group I: Dose Expansion in solid tumors Experimental Treatment 1 Intervention

Participants with other MTAP-deleted solid tumors will receive TNG908 at the identified RP2D

Group II: Dose Expansion in Sarcoma Experimental Treatment 1 Intervention

Participants with MTAP-deleted sarcoma (soft tissue and bone) will receive TNG908 at the identified RP2D

Group III: Dose Expansion in Pancreatic Ductal Adenocarcinoma Experimental Treatment 1 Intervention

Participants with MTAP-deleted pancreatic ductal adenocarcinoma will receive TNG908 at the identified RP2D

Group IV: Dose Expansion in NSCLC Experimental Treatment 1 Intervention

Participants with MTAP-deleted NSCLC (squamous and non squamous) will receive TNG908 at the identified RP2D

Group V: Dose Expansion in Mesothelioma Experimental Treatment 1 Intervention

Participants with MTAP-deleted mesothelioma will receive TNG908 at the identified RP2D

Group VI: Dose Expansion in Glioblastoma Experimental Treatment 1 Intervention

Participants with MTAP-deleted relapsed/refractory glioblastoma will receive TNG908 at the identified RP2D

Group VII: Dose Escalation Experimental Treatment 1 Intervention

Participants with MTAP-deleted solid tumors will receive escalating doses of TNG908 to estimate the MTD

Who Is Running the Clinical Trial?

Tango Therapeutics, Inc.

Lead Sponsor

Trials

5

Recruited

740+